全 文 ： 527 Journal of Chinese Pharmaceutical Sciences http://www.jcps.ac.cn
Sesquiterpenes from the aerial parts of Artemisia vestita Wall.
Shuaihua Tian, Helin Wei, Mingbo Zhao, Chen Zhang, Pengfei Tu*
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science
Center, Beijing 100191, China
Abstract: A chemical investigation of the aerial parts of Artemisia vestita Wall. led to the isolation of 12 known sesquiterpenes, including
2 furan-containing sesquiterpenoids and 10 eudesmane sesquiterpene lactones. Their structures were identified as negunfurol (1),
schensianol A (2), artemine (3), erivanin (4), 1,5-diepi-artemin (5), acetylartemin (6), naphtho[1,2-b]furan-2(3H)-one, 6-(acetyloxy)
decahydro-9a-hydroxy-3,5a-dimethyl-9-methylene-(3S,3aS,5aS,6S,9aS,9bS) (7), naphtho[1,2-b]furan-2(3H)-one, 6-(acetyloxy)-
3a,4,5,5a,6,7,8,9b-octahydro-8-hydroxy-3,5a,9-trimethyl- (3S,3aS,5aR,6S,8S,9bS) (8), isoerivanin (9), barrelierin (10), (11S)-1-
oxoeudesm-4(14)-eno-13,6α-lactone (11), 1-epi-dehydroisoeranin (12), respectively. All of these compounds were isolated from
Artemisia vestita for the first time, and compounds 1 and 2 were isolated from the genus Artemisia for the first time.
Keywords: Artemisia vestita; Sesquiterpene lactones; Eudesmane; Furan-containing sesquiterpenoid; Chemical constituents
CLC number: R284 Document code: A Article ID: 1003–1057(2013)5–527–04
Received: 2013-03-30; Revised: 2013-04-15; Accepted: 2013-04-29.
Foundation items: National Natural Science Foundation of China
(Grant No. 30973629) and National Key Technology R&D Program
“New Drug Innovation” of China (Grant No. 2012ZX09301002-002-002,
2012ZX09304-005).
*Corresponding author. Tel.: 86-10-82802750;
E-mail: pengfeitu@vip.163.com
http://dx.doi.org/10.5246/jcps.2013.06.077
1. Introduction
Artemisia vestita Wall. (Chinese name: Maolianhao) is
a medicinal plant of the genus Artemisia in the Compositae
family with a wide distribution in the western areas of
China[1]. Its aerial parts have been used to treat various
inflammatory diseases as a folk medicine in Tibet. Pre-
viously, only one phytochemical investigation was con-
ducted, which revealed the presence of flavonoids, coumarins,
and sesquiterpene lactones[2]. Another paper showed that
the extracts of A. vestita could alleviate picryl chloride
(PC)-induced contact hypersensitivity through blocking
the activation of T lymphocytes[3]. Attracted by the diverse
structures and significant biological activities of sesquiter-
penoids from the Artemisia plants[4–7], our group has dedi-
cated on the systematic research of sesquiterpenes from
genus Artemisia, devoting great efforts to discoveries of new
and/or biologically active sesquiterpenoids[8–10]. As part of
the systematic research, the chloroform extract of the aerial
parts of A. vestita was investigated, leading to the isolation
of 12 known sesquiterpenes, including 2 furan-containing
sesquiterpenoids and 10 eudesmane-type sesquiterpene
lactones. Based on the analysis of spectroscopic data and
comparison with those in literature, their structures were
identified as negunfurol (1), schensianol A (2), artemine (3),
erivanin (4), 1,5-diepi-artemin (5), acetylartemin (6), naphtho
[1,2-b]furan-2(3H)-one, 6-(acetyloxy)decahydro-9a-hydroxy-
3,5a-dimethyl-9-methylene-(3S,3aS,5aS,6S,9aS,9bS) (7),








naphtho[1,2-b]furan-2(3H)-one, 6-(acetyloxy)-3a,4,5,5a,
6,7,8,9b-octahydro-8-hydroxy-3,5a,9-trimethyl-(3S,3aS,
5aR, 6S,8S,9bS) (8), isoerivanin (9), barrelierin (10),
(11S)-1-oxoeudesm-4(14)-eno-13,6α-lactone (11), and
1-epi-dehydroisoeranin (12) (Fig. 1). Compounds 1 and 2
were isolated from this genus for the first time, and all
others were isolated from this plant for the first time.
2. Experimental
2.1. General procedures
NMR spectra were recorded on a Varian 500 spectrometer,
operating at 500 MHz for 1H NMR and 125 MHz for
13C NMR. The chemical shifts were given in δ (ppm) with
deuterated solvents as the internal standard and coupling
constants (J) were expressed in units of Hertz (Hz). EI-MS
was performed on an MDS-SCIEX-QSTAR instrument.
ESI-MS was measured on an Aglient 6320 ion-trap mass
spectrometer. Semi-preparative HPLC was achieved on
a Dionex Ultimate 3000 HPLC system equipped with
an ODS column (Thermo Scientific BDS-C18 column,
250 mm×10 mm, 5 μm) and a guard column. Column
chromatography (CC) was performed with silica gel
(200–300 mesh, Qingdao Haiyang Chemical Inc., China),
ODS (50 μm, Merck, Germany), and Sephadex LH-20
(Amersham Biosciences, Sweden). Analytical grade and
HPLC-grade solvents were purchased from Beijing
Chemical Factory. All solutions were filtered through
a 0.45 μm hydrophilic polypropylene membrane before
being subjected to HPLC system.
2.2. Plant materials
The aerial parts of A. vestita were collected from Yunnan
Province in September 2010. The material was authenticated
by one of the authors (Prof. Pengfei Tu). A voucher specimen
(No. 20100905) is deposited at the Herbarium of the
Peking University Modern Research Center for Tradi-
tional Chinese Medicine.
2.3. Extraction and isolation
The dried aerial parts (45 kg) of A. vestita were extracted
with 95% ethanol (360 L×3 h×3) at room temperature.
The concentrated extract (3.8 kg) was suspended in H2O
(15 L) and partitioned with petroleum ether (PE) and
chloroform (CHCl3) successively. The CHCl3 extract
(450 g) was subjected to a silica gel column, eluting with
a step-wise gradient of PE–EtOAc (1:0, 8:1, 3:1, 1:1, 0:1,
v/v) to produce 10 fractions (Frs. 1–10), monitored by TLC.
Fr. 2 was subjected to silica gel CC (200–300 mesh),
eluting with a gradient of CHCl3–acetone (10:1–1:1, v/v)
to obtain sub-Frs. 2-1–2-4. Compounds 1 (3 mg) and 2
(2 mg) were obtained from sub-Fr. 2-2 successively by
p-TLC (n-hexane–acetone, 8:1, v/v) and semi-preparative
HPLC (MeCN–H2O, 60:40, v/v). Fr. 4 was further
fractionated by silica gel CC (200–300 mesh), eluting
with a gradient of n-hexane–acetone (10:1–1:1, v/v),
followed by Sephadex LH-20 CC (CHCl3–MeOH, 2:1, v/v),
then purified by an opening ODS CC, eluting with MeCN–
H2O (50:50, v/v) to yield compounds 10 (10 mg), 11 (4 mg)
and 12 (5 mg). Fr. 5 was further loaded onto silica gel CC
(200–300 mesh), eluting a gradient of n-hexane–acetone
(8:1–1:1, v/v) to obtain sub-Frs. 5-1–5-6. Compounds 7
(57 mg), 8 (14 mg) and 9 (6 mg) were obtained from
the sub-Fr. 5-5 by p-TLC (n-hexane–acetone, 4:1, v/v).
Compounds 3 (5 mg), 4 (11 mg), 5 (23 mg), and 6 (8 mg)
were obtained from the sub-Fr. 5-6 by an opening ODS
CC (MeCN–H2O, 35:75, v/v).
3. Identification
3.1. Negunfurol (1)
Colorless oil; ESI-MS m/z 277 [M+Na]+; 1H NMR
(500 MHz, CDCl3) δ: 5.92 (dd, 1H, J1 11.0 Hz, J2 16.5 Hz,
H-2), 5.64 (dd, 1H, J1 6.5 Hz, J2 16.0 Hz, H-5), 5.59 (d,
1H, J 16.0 Hz, H-6), 5.21 (d, 1H, J 16.5 Hz, H-1a), 5.07
(d, 1H, J 11.0 Hz, H-1b), 3.77 (dt, 1H, J1 4.0 Hz, J2 7.0 Hz,
H-10), 2.23 (m, 1H, H-4), 1.88 (m, 2H, H-8), 1.83 (m,
2H, H-9), 1.31 (s, 3H, H-14), 1.27 (s, 3H, H-12), 1.22 (s,
3H, H-15), 1.13 (s, 3H, H-13); 13C NMR (125 MHz,
CDCl3) data see Table 1. These data were in good agree-
ment with those of negunfurol[11].
3.2. Schensianol A (2)
Colorless oil; ESI-MS m/z 277 [M+Na]+; 1H NMR
(500 MHz, CDCl3) δ: 5.91 (dd, 1H, J1 11.0 Hz, J2 16.5 Hz,
H-2), 5.70 (dd, 1H, J1 6.5 Hz, J2 16.0 Hz, H-5), 5.61 (d,
1H, J 16.0 Hz, H-6), 5.22 (d, 1H, J 16.5 Hz, H-1a), 5.08
(d, 1H, J 11.0 Hz, H-1b), 3.86 (dt, 1H, J1 4.0 Hz, J2 7.0 Hz,
H-10), 2.24 (m, 1H, H-4), 1.89 (m, 2H, H-8), 1.81 (m,
2H, H-9), 1.32 (s, 3H, H-14), 1.28 (s, 3H, H-12), 1.24 (s,
3H, H-15), 1.14 (s, 3H, H-13); 13C NMR (125 MHz,
CDCl3) data see Table 1. These data were in good agree-
ment with those of schensianol A[11].
3.3. Artemine (3)
Colorless needle; mp: 260–262 °C; ESI-MS m/z 289
[M+Na]+; 1H NMR (500 MHz, CDCl3) δ: 5.03 (br s, 1H,
H-15a), 4.98 (br s, 1H, H-15b), 4.26 (d, 1H, J 10.5 Hz, H-6),
4.16 (dd, 1H, J1 5.0 Hz, J2 11.5 Hz, H-1), 2.66 (m, 1H, H-3α),
2.36 (m, 1H, H-7), 2.35 (m, 1H, H-11), 2.17 (m, 1H, H-3β),
1.86 (m, 1H, H-8α), 1.85 (m, 1H, H-9β), 1.74 (m, 1H, H-2α),
1.61 (m, 1H, H-2β), 1.60 (m, 1H, H-9α), 1.56 (m, 1H, H-8β),
1.25 (d, 3H, H-13), 0.90 (s, 3H, H-14); 13C NMR (125 MHz,
CDCl3) data see Table 1. These data were in good agree-
ment with those of artemine[12].
3.4. Erivanin (4)
Colorless crystal; mp: 203–205 °C; ESI-MS m/z 289
[M+Na]+; 1H NMR (500 MHz, CDCl3) δ: 5.19 (br s, 1H,
H-15a), 5.06 (br s, 1H, H-15b), 4.43 (s, 1H, H-3), 4.05 (t,
1H, J 11.0 Hz, H-6), 3.37 (s, 1H, H-1), 3.03 (d, 1H, J 11.0 Hz,
H-5), 2.35 (dq, 1H, J1 7.0 Hz, J2 11.0 Hz, H-11), 2.16
528 Tian, S.H. et al. / J. Chin. Pharm. Sci. 2013, 22 (6), 527–530
Figure 1. Chemical structures of compounds 1–12.
7 8 9 10 11 12
1
2 3 4 5 6
O
HO
OH
1
3
5
7
8
10
11
13
1415
O
HO
OH
1
4 6
10
11
13
14
15
O
OH
OH
O
O
OH
O
HO
O
OH
O
OH O
OAc
O
OH
O
OAc
O
OH
O
OAc
O
HO
O
OH
O
HO
O
O
O
O
O
O
O O OH
O
529 Tian, S.H. et al. / J. Chin. Pharm. Sci. 2013, 22 (6), 527–530
(m, 1H, H-9β), 2.01 (m, 1H, H-2β), 1.97 (m, 1H, H-2α),
1.91 (m, 1H, H-9α), 1.72 (dq, 1H, J1 3.5 Hz, J2 11.0 Hz,
H-7), 1.55 (m, 1H, H-8α), 1.35 (m, 1H, H-8β), 1.24 (d, 3H,
J 7.0 Hz, H-13), 0.81 (s, 3H, H-14); 13C NMR (125 MHz,
CDCl3) data see Table 1. These data were in good accor-
dance with those of erivanin[13].
3.5. 1,5-diepi-Artemin (5)
Colorless oil; ESI-MS m/z 289 [M+Na]+; 1H NMR
(500 MHz, CDCl3) δ: 5.06 (s, 1H, H-15α), 5.01 (s, 1H,
H-15β), 4.41 (d, 1H, J 11.5 Hz, H-6), 3.95 (dd, 1H, J1 4.5 Hz,
J2 12.0 Hz, H-1), 2.61 (m, 1H, H-3β), 2.33 (m, 1H, H-7),
2.31 (m, 1H, H-11), 2.14 (m, 1H, H-3α), 1.88 (m, 1H,
H-8α), 1.76 (m, 1H, H-2β), 1.66 (m, 1H, H-2α), 1.64 (m,
1H, H-9α), 1.50 (m, 1H, H-8β), 1.49 (m, 1H, H-9β), 1.26
(s, 3H, H-14), 1.23 (d, 3H, J 6.5 Hz, H-13); 13C NMR
(125 MHz, CDCl3) data see Table 1. These data were in
good accordance with those of 1,5-diepi-artemin[12].
3.6. Acetylartemin (6)
White amorphous powder; ESI-MS m/z 331 [M+Na]+;
1H NMR (500 MHz, CDCl3) δ: 5.07 (s, 1H, H-15α), 5.05
(s, 1H, H-15β), 4.80 (t, 1H, J 3.0 Hz, H-1), 4.17 (d, 1H,
J 11.0 Hz, H-6), 2.75 (m, 1H, H-3α), 2.51 (m, 1H, H-7),
2.31 (m, 1H, H-11), 2.16 (s, 3H, CH3COO), 2.13 (m, 1H,
H-3β), 2.02 (m, 1H, H-2α), 2.00 (m, 1H, H-9α), 1.84 (m,
1H, H-2β), 1.82 (m, 1H, H-8α), 1.54 (m, 1H, H-8β), 1.21 (m,
1H, H-9β), 1.22 (d, 3H, J 6.5 Hz, H-13), 1.03 (s, 3H, H-14);
13C NMR (125 MHz, CDCl3) data see Table 1. These data
were in good accordance with those of acetylartemin[12].
3.7. Naphtho[1,2-b]furan-2(3H)-one,6-(acetyloxy)
decahydro-9a-hydroxy-3,5a-dimethyl-9-methylene-
(3S,3aS,5aS,6S,9aS,9bS) (7)
White amorphous powder; ESI-MS m/z 331 [M+Na]+;
1H NMR (500 MHz, CDCl3) δ: 5.09 (dd, 1H, J1 4.5 Hz,
J2 12.0 Hz, H-1), 5.04 (s, 1H, H-15α), 5.00 (s, 1H, H-15β),
4.36 (d, 1H, J 10.0 Hz, H-6), 2.66 (m, 1H, H-3β), 2.32 (m,
1H, H-11), 2.28 (m, 1H, H-7), 1.99 (s, 3H, CH3COO),
1.83 (m, 1H, H-2β), 1.82 (m, 1H, H-8α), 1.61 (m, 1H,
H-2α), 1.60 (m, 1H, H-9β), 1.58 (m, 1H, H-9α), 1.49 (m,
1H, H-8β), 1.19 (d, 3H, J 5.0 Hz, H-13), 1.09 (s, 3H, H-14);
13C NMR (125 MHz, CDCl3) data see Table 1. These data
were in good accordance with those of compound 15 in
the literature[12].
3.8. Naphtho[1,2-b]furan-2(3H)-one,6-(acetyloxy)-
3a,4,5,5a,6,7,8,9b-octahydro-8-hydroxy-3,5a,9-trimethyl-
(3S,3aS,5aR,6S,8S,9bS) (8)
White amorphous powder; ESI-MS m/z 331 [M+Na]+;
1H NMR (500 MHz, CDCl3) δ: 4.96 (dd, 1H, J1 2.5 Hz,
J2 7.5 Hz, H-1), 4.56 (dd, J1 1.5 Hz, J2 11.0 Hz, H-6),
4.08 (dd, 1H, J1 5.5 Hz, J2 7.0 Hz, H-3α), 2.26 (m, 1H,
H-11), 2.12 (m, 1H, H-2α), 2.08 (s, 3H, CH3COO), 2.01
(s, 3H, H-15), 1.96 (m, 1H, H-8α), 1.93 (m, 1H, H-2β),
1.75 (m, 1H, H-7), 1.62 (m, 1H, H-8β), 1.59 (m, 1H, H-9α),
1.44 (m, 1H, H-9β), 1.23 (d, 3H, J 7.0 Hz, H-13), 1.16 (s,
3H, H-14); 13C NMR (125 MHz, CDCl3) data see Table 1.
These data were in good accordance with those of
compound 17 in the literature[12].
3.9. Isoerivanin (9)
Colorless oil; ESI-MS m/z 289 [M+Na]+; 1H NMR
(500 MHz, CDCl3) δ: 4.55 (d, 1H, J 11.0 Hz, H-6), 3.95
(s, 1H, H-3), 3.54 (s, 1H, H-1), 2.27 (m, 1H, H-11), 2.16
(m, 1H, H-9α), 2.12 (m, 1H, H-2β), 2.09 (m, 1H, H-2α),
2.06 (s, 3H, H-15), 1.99 (m, 1H, H-9β), 1.83 (m, 1H, H-7),
1.56 (m, 1H, H-8β), 1.39 (m, 1H, H-8α), 1.26 (d, 1H,
J 7.0 Hz, H-13), 1.08 (s, 3H, H-14); 13C NMR (125 MHz,
CDCl3) data see Table 1. These data were in good accor-
dance with those of isoerivanin[13].
Table 1. 13C NMR data of compounds 1–12 (125 MHz, CDCl3)
No.
Compounds
1 2 3 4 5 6 7 8 9 10 11 12
1 111.9 111.9 71.7 74.6 73.0 78.3 75.6 75.9 74.6 213.4 212.0 74.3
2 144.8 144.8 29.6 32.9 30.1 27.1 26.5 33.4 32.2 35.9 34.0 42.4
3 72.6 72.6 29.9 75.5 31.7 26.6 31.3 69.4 70.7 33.0 37.6 196.8
4 45.1 45.1 144.9 145.6 144.2 144.4 143.4 128.3 131.1 129.9 140.8 129.4
5 122.1 122.4 76.5 42.3 75.3 76.4 75.1 130.2 126.3 126.9 52.3 152.3
6 140.2 140.7 81.7 79.6 86.0 81.3 85.5 82.2 82.7 80.8 78.6 81.9
7 82.7 82.5 45.4 52.4 47.5 44.9 47.2 52.4 52.4 48.3 51.8 52.1
8 37.8 38.3 22.8 22.9 23.7 22.4 23.5 23.7 24.0 20.7 22.5 24.3
9 26.4 26.5 30.3 33.9 26.4 28.7 27.5 30.9 33.8 34.6 31.5 37.9
10 85.4 85.6 44.5 43.5 46.1 43.2 45.1 40.9 42.3 48.6 50.3 43.7
11 71.2 71.2 41.2 41.2 42.1 41.0 41.9 40.7 41.1 37.9 41.1 41.1
12 27.1 27.3 179.3 179.4 178.6 178.4 178.3 178.4 178.6 179.3 178.8 177.6
13 24.1 24.3 12.4 12.5 12.6 12.4 12.5 12.6 12.4 9.6 12.5 12.4
14 26.6 26.5 13.2 17.7 17.5 20.6 17.3 25.2 18.0 23.3 18.1 17.5
15 27.4 27.5 112.4 113.1 115.2 111.9 115.5 17.8 25.3 19.7 112.7 11.2
CH3COO 169.4 170.4 169.9
CH3COO 21.2 21.0 21.3
3.10. Barrelierin (10)
Colorless needle; mp: 118–119 ºC; EI-MS: m/z 248 [M]+;
1H NMR (500 MHz, CDCl3) δ: 4.81 (dd, 1H, J1 1.0 Hz,
J2 11.0 Hz, H-6), 2.64 (m, 1H, H-11), 2.61 (m, 1H, H-2β),
2.47 (m, 1H, H-2α), 2.39 (m, 1H, H-3β), 2.34 (m, 1H, H-3α),
2.17 (m, 1H, H-7), 1.94 (s, 3H, H-15), 1.84 (m, 1H, H-9β),
1.81 (m, 1H, H-8α), 1.66 (m, 1H, H-8β), 1.51 (m, 1H,
H-9α), 1.30 (s, 3H, H-14), 1.19 (d, 3H, J 7.5 Hz, H-13);
13C NMR (125 MHz, CDCl3) data see Table 1. These data
were in good accordance with those of barrelierin[14].
3.11. (11S)-1-Oxoeudesm-4(14)-eno-13,6α-lactone (11)
Colorless needle; mp: 152–154 ºC; EI-MS: m/z 248 [M]+;
1H NMR (500 MHz, CDCl3) δ: 5.22 (s, 1H, H-15α), 5.07
(s, 1H, H-15β), 4.13 (t, 1H, J 10.5 Hz, H-6), 2.69(m, 1H,
H-3a), 2.61 (m, 1H, H-3β), 2.42 (m, 1H, H-5), 2.35 (m,
1H, H-11), 2.17 (m, 1H, H-2a), 1.97 (m, 1H, H-2β),
1.88 (m, 1H, H-8α), 1.85 (m, 1H, H-9α), 1.79 (m, 1H,
H-9β), 1.79 (m, 1H, H-7), 1.64 (m, 1H, H-8β), 1.24 (d,
3H, J 7.5 Hz, H-13), 1.13 (s, 3H, H-14); 13C NMR
(125 MHz, CDCl3) data see Table 1. These data were in
good accordance with those of (11S)-1-oxoeudesm-4(14)-
eno-13,6α-lactone[15].
3.12. 1-epi-Dehydroisoeranin (12)
Colorless crystal; mp: 137–138 ºC; ESI-MS: m/z 287
[M+Na]+; 1H NMR (500 MHz, CDCl3) δ: 4.76 (dd, 1H,
J1 1.5 Hz, J2 11.5 Hz, H-6), 3.88 (dd, 1H, J1 5.0 Hz,
J2 13.5 Hz, H-1), 2.68 (m, 1H, H-2α), 2.58 (m, 1H, H-2β),
2.37 (m, 1H, H-11), 2.25 (m, 1H, H-9α), 2.04 (m, 1H, H-8α),
2.02 (d, 1H, J 1.5 Hz, H-15), 1.92 (m, 1H, H-8β), 1.65 (m,
1H, H-7), 1.46 (m, 1H, H-9β), 1.29 (s, 3H, H-14), 1.28 (d,
1H, J 7.0 Hz, H-13); 13C NMR (125 MHz, CDCl3) data
see Table 1. These data were in good accordance with
those of 1-epi-dehydroisoeranin[16,17].
Acknowledgements
This work was financially supported by the grants from
the National Natural Science Foundation of China (Grant
No. 30973629) and National Key Technology R&D
Program “New Drug Innovation” of China (Grant No.
2012ZX09301002-002-002, 2012ZX09304-005).
References
[1] Editorial Committee of Flora of China, Flora of China. 1992,
76, 49.
[2] Bai, Y.J.; Li, Y.; Shi, Y.P. Chin. Pharm. J. 1997, 32, 462–465.
[3] Wang, J.L.; Sun, Y.; Li, Y.H.; Xu, Q. Int. Immunopharmacol.
2005, 28, 407–415.
[4] Fraga, B.M. Nat. Prod. Rep. 2010, 27, 1681–1708.
[5] Fraga, B.M. Nat. Prod. Rep. 2011, 28, 1580–1610.
[6] Fraga, B.M. Nat. Prod. Rep. 2012, 29, 1334–1366.
[7] Zhan, Z.J.; Ying, Y.M.; Ma, L.F.; Shan, W.G. Nat. Prod.
Rep. 2011, 28, 594–629.
[8] Wen, J.; Shi, H.M.; Tu, P.F. J. Nat. Prod. 2010, 73, 67–70.
[9] Zan, K.; Chai, X.Y.; Tu, P.F. Tetrahedron. 2012, 68,
5060–5065.
[10] Wang, S.; Li, J.; Tu, P.F. Fitoterapia. 2013, 85, 169–175.
[11] Zheng, C.J.; Pu, J.; Qin, L.P.C. Fitoterapia. 2012, 83, 49–54.
[12] Marco, J.A.; Sanz-Cervera, J.F.; Pareja, J.M. Phytochemistry.
1994, 37, 477–485.
[13] Boriky, D.; Berrada, M.; Talbi, M. Phytochemistry. 1996,
43, 309–311.
[14] Sanz, J.F.; Castellano, G.; Marco, J.A. Phytochemistry.
1990, 29, 541–545.
[15] Yuuya, S.; Hagiwara, H.; Suzuki, T. J. Nat. Prod. 1999, 62,
22–30.
[16] Rustaiyan, A.; Sigari, H.; Jakupovic, J.; Grenz, M. Phyto-
chemistry. 1989, 28, 2723–2725.
[17] Hashimoto, T.; Noma, Y.; Asakawa, Y. Heterocycyles. 2001,
54, 529–559.
Tian, S.H. et al. / J. Chin. Pharm. Sci. 2013, 22 (6), 527–530 530
毛莲蒿中倍半萜类化学成分研究
田帅华, 魏荷琳, 赵明波, 章宸, 屠鹏飞*
北京大学医学部 药学院 天然药物及仿生药物国家重点实验室, 北京 100191
摘要: 研究蒿属植物毛莲蒿地上部分倍半萜类化学成分, 通过硅胶柱色谱、反相硅胶柱色谱、制备高效液相色谱等
色谱方法分离得到12个倍半萜类成分, 经多种波谱方法鉴定其结构, 分别为negunfurol (1), schensianol A (2), artemine (3),
eudesm-4(14)-en-12-oic acid, erivanin (4), 1,5-diepi-artemin (5), acetylartemin (6), naphtho[1,2-b]furan-2(3H)-one,6-(acetyloxy)-
decahydro-9a-hydroxy-3,5a-dimethyl-9-methylene-(3S,3aS,5aS,6S,9aS,9bS) (7), naphtho[1,2-b]furan-2(3H)-one,6-(acetyloxy)-
3a,4,5,5a,6,7,8,9b-octahydro-8-hydroxy-3,5a,9-trimethyl-(3S,3aS,5aR,6S,8S,9bS) (8), isoerivanin (9), barrelierin (10), (11S)-1-
oxoeudesm-4(14)-eno-13,6α-lactone (11), 1-epi-dehydroisoeranin (12)。其中化合物1和2为首次从蒿属植物中分离得到, 其它
化合物均为首次从毛莲蒿中分离得到。
关键词: 毛莲蒿; 倍半萜内酯; 桉叶烷; 呋喃型倍半萜; 化学成分